Welcome to Longboard Pharmaceuticals. The Next Wave of Neurological Medicines is Here. We are committed to transforming the lives of patients with neurological and rare diseases.

Longboard Pharmaceuticals is a clinical-stage biopharmaceutical company focused on developing novel, transformative medicines for neurological diseases, with an initial focus on rare diseases.

Oct 14, 2024 · Lundbeck A/S (Lundbeck) and Longboard Pharmaceuticals, Inc (NASDAQ: LBPH) (Longboard) today announced an agreement for Lundbeck to acquire Longboard. Under the terms of the agreement, Lundbeck will commence a tender offer for all outstanding shares of Longboard common stock, whereby Longboard shareholders will be offered a payment of USD 60.00 ...

Longboard was formed in January 2020 by Arena Pharmaceuticals, Inc. (acquired by Pfizer) to advance a portfolio of centrally-acting product candidates designed to be highly selective for specific G protein-coupled receptors (GPCRs).

Oct 17, 2024 · Lundbeck and Longboard Pharmaceuticals have announced an agreement for the Danish pharmaceutical company to acquire all outstanding shares of Longboard, in a transaction valued at $2.6 billion in equity value. The transaction is expected to close by the end of the year.

Longboard is a clinical-stage biopharmaceutical company focused on developing novel, transformative medicines for neurological diseases.

Jan 2, 2024 · LA JOLLA, Calif.-- (BUSINESS WIRE)-- Longboard Pharmaceuticals, Inc. (Nasdaq: LBPH), a clinical-stage biopharmaceutical company focused on developing novel, transformative medicines for...

FDA has granted Breakthrough Therapy Designation. Expected launch in the fourth quarter of 2028. Global peak sales potential estimated at USD 1.5-2 billion, complementing our mid- to late-stage development pipeline and diversifying revenue growth. DEEs: Developmental and Epileptic Encephalopathies. DS: Dravet syndrome. LGS: Lennox-Gastaut syndrome.

New York – October 14, 2024 – Cooley advised Longboard Pharmaceuticals (Nasdaq: LBPH), a clinical-stage biopharmaceutical company focused on developing novel, transformative medicines for neurological diseases, on its $2.6 billion sale to Lundbeck.

Longboard Pharmaceuticals, Inc. is a clinical-stage biopharmaceutical company focused on developing novel, transformative medicines for neurological diseases. Longboard is working to advance a...